生物制剂在银屑病患者中的应用——基于真实世界数据的回顾性分析。

Use of biologics in patients with psoriasis - A retrospective analysis based on real-world data.

机构信息

Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.

National Clinical Research Center for Dermotologic Diseases and Immunologic Diseases, Beijing, China.

出版信息

Skin Res Technol. 2024 Jan;30(1):e13550. doi: 10.1111/srt.13550.

DOI:10.1111/srt.13550

PMID:38174801

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10765354/

Abstract

OBJECTIVE

To summarize and analysis the application of biologic agents in patients with psoriasis in the real world.

METHODS

Relying on collected data from June 2020 to September 2021 in the database of China Psoriasis Standardized Diagnosis and Treatment Center, 2529 cases of psoriasis patients treated with biologic agents in 188 different tertiary hospitals across China were retrospective analyzed. The collected information mainly includes demographic data (age, gender, psoriasis history), curative effectiveness of used biologics drug withdrawal and its reason. According to the collected information, condition of the usage for each category of biologics and influencing factor of biologics replacement were analyzed.

RESULT

A total of 2529 patients were analyzed, which included 1626 male (64.29%) and 903 female (35.71%) with an average age of 42.12 ± 14.70 (17 ∼ 85) years old; 2336 (92.37%) patients were aged from 19 to 60 years old. Within these patients, 2362 of them (93.40%) had a psoriasis area and severity index (PASI) score, and 1776 of these patients had moderate to severe cases (75.19%). According to the patient's self-evaluation of the past efficacy of biological agents, secukinumab was chosen by the most people to have the highest efficacy (1140 cases, 93.60%). The main reason for the withdrawal of secukinumab is that the disease is already well controlled at the time of withdrawal (67 cases, 38.95%); for TNF- α inhibitor is the poor curative effect; for ustekinumab and ixekizumab were the non-affordable price.

CONCLUSIONS

In the current biotherapy of psoriasis in China, the efficacy of secukinumab is thought by most people to be the highest. Secukinumab is the first choice when the needs of changing biologics appear.

摘要

目的

总结和分析生物制剂在真实世界中治疗银屑病患者的应用。

方法

依托中国银屑病规范化诊疗中心数据库，收集 2020 年 6 月至 2021 年 9 月期间全国 188 家三级医院应用生物制剂治疗的 2529 例银屑病患者的临床资料，回顾性分析患者的人口学资料（年龄、性别、银屑病病史）、生物制剂停药疗效及其原因。根据收集的信息，分析各类生物制剂的使用情况及影响生物制剂替换的因素。

结果

共分析 2529 例患者，其中男 1626 例（64.29%），女 903 例（35.71%），平均年龄为 42.12±14.70（17～85）岁；2336 例（92.37%）患者年龄在 19～60 岁之间。在这些患者中，2362 例（93.40%）有银屑病面积和严重程度指数（PASI）评分，1776 例（75.19%）为中重度患者。根据患者对生物制剂过去疗效的自我评估，司库奇尤单抗被选择的人数最多，疗效最高（1140 例，93.60%）。司库奇尤单抗停药的主要原因是停药时疾病已得到很好控制（67 例，38.95%）；TNF-α 抑制剂停药的主要原因为疗效不佳；乌司奴单抗和依奇珠单抗停药的主要原因为价格不可承受。